. Author manuscript; available in PMC: 2014 Sep 5.

Published in final edited form as: J Urol. 2013 Oct 19;191(5):1446–1453. doi: 10.1016/j.juro.2013.10.065

Table 1.

Demographic characteristics of 93 study participants and positive scan locations

Age:
Mean ± SD	68.0 ± 7.6
Median (range)	68.0 (49–90)
Q1, Q3	63.0, 73.3
PSA (ng/ml):
Mean ± SD	9.8 ± 31.5
Median (range)	4.0 (0.11–301.7)
Q1, Q3	1.8, 9.7
No. original prostate Ca therapy (%):
Prostatectomy with/without other treatments	24 (25.8)
Nonprostatectomy alone or combined	69 (74.2)
Original Gleason score:^*
Mean ± SD	6.9 ± 0.8
Median (range)	7.0 (5–10)
Q1, Q3	6.0, 7.0
No. Gleason score (%):^*
3 + 4 or Less	52 (60.5)
4 + 3 or Greater	34 (39.5)
No. anti-3-[¹⁸F]FACBC pos scan (%):
Whole body	77 (82.8)
Prostate only	49 (63.6)
Prostatic + extraprostatic	24 (31.2)
Extraprostatic only	4 (5.2)
No. ¹¹¹In-capromab pendetide pos scan (%):
Whole body	56 (60.2)
Prostate only	46 (82.1)
Prostatic + extraprostatic	9 (16.1)
Extraprostatic only	1 (1.8)

Unavailable in 7 patients.